Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs
- 24 January 2020
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (3), 1902048
- https://doi.org/10.1183/13993003.02048-2019
Abstract
Background Clinical trials suggest less hepatotoxicity and better adherence with 4 months rifampin (4R) versus 9 months isoniazid (9H) for treating latent tuberculosis infection (LTBI). Our objectives were to compare frequencies of severe hepatic adverse events and treatment completion, and direct health system costs of LTBI regimens 4R and 9H, in the general population of the province of Quebec, Canada, using provincial health administrative data. Methods Our retrospective cohort included all patients starting rifampin or isoniazid regimens between 2003 and 2007. We estimated hepatotoxicity from hospitalisation records, treatment completion from community pharmacy records, and direct costs from billing records and fee schedules. We compared rifampin to isoniazid using logistic (hepatotoxicity), log-binomial (completion), and gamma (costs) regression, with adjustment for age, co-morbidities, and other confounders. Results 10 559 individuals started LTBI treatment (9684 isoniazid; 875 rifampin). Rifampin patients were older with more baseline co-morbidities. Severe hepatotoxicity risk was higher with isoniazid (n=15) than rifampin (n=1), adjusted OR=2.3 (95%CI: 0.3,16.1); there were 2 liver transplants and 1 death with isoniazid and none with rifampin. Overall, patients without co-morbidities had lower hepatotoxicity risk (0.1% versus 1.0%). 4R completion (53.5%) was higher than 9H (36.9%), adjusted RR=1.5 (95%CI:1.3,1.7). Mean costs per patient were lower for rifampin than isoniazid: adjusted Cost Ratio=0.7 (95%CI:0.5,0.9). Conclusion Risk of severe hepatotoxicity and direct costs were lower, and completion was higher, for 4R than 9H, after adjustment for age and co-morbidities. Severe hepatotoxicity resulted in death or liver transplant in three patients receiving 9H, compared to no patients receiving 4R.Funding Information
- Canadian Institutes of Health Research
This publication has 24 references indexed in Scilit:
- Psychiatric Morbidity and Other Factors Affecting Treatment Adherence in Pulmonary Tuberculosis PatientsTuberculosis Research and Treatment, 2013
- European Union Standards for Tuberculosis CareEuropean Respiratory Journal, 2012
- Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TBThorax, 2010
- Adherence to treatment of latent tuberculosis infection in a clinical population in New York CityInternational Journal of Infectious Diseases, 2009
- A Retrospective Evaluation of Completion Rates, Total Cost, and Adverse Effects for Treatment of Latent Tuberculosis Infection in a Public Health Clinic in Central MassachusettsClinical Infectious Diseases, 2009
- Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative dataBMC Health Services Research, 2007
- Public/Private Partnerships for Prescription Drug Coverage: Policy Formulation and Outcomes in Quebec's Universal Drug Insurance Program, with Comparisons to the Medicare Prescription Drug Program in the United StatesThe Milbank Quarterly, 2007
- Safety and Completion Rate of Short‐Course Therapy for Treatment of Latent Tuberculosis InfectionClinical Infectious Diseases, 2006
- A comparison of multivariable regression models to analyse cost dataJournal of Evaluation in Clinical Practice, 2006
- Detection, verification, and quantification of adverse drug reactionsBMJ, 2004